PCVX Vaxcyte, Inc. stock chart & analysis
Conviction 32HealthcareScan · Fri, Nov 6, 2026Vaxcyte, Inc. (PCVX) closed at $63.89 (+3.18%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 53, RS Rating 94, -29.6% from its 52-week high, +38.5% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Financials as of Wed, Sep 30, 2026 · quarterly.
PCVX technical analysis
Trend
PCVX is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 3.5% above the 50-day ($61.71) and 11.3% above the 200-day ($57.37). ADX(14) at 26 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 53, in the bullish half of its range. The MACD histogram is negative. Its RS Rating of 94 puts its weighted 12-month performance ahead of about 94% of the US market.
Volume and volatility
Volume on the latest session ran 0.8× its 20-day average. It trades about $141.3M a day on average. ATR(14) is $3.61, 5.7% of price — its typical daily range. Chaikin Money Flow (-0.27) shows distribution.
Key levels
The chart pattern's support is $55.46 and its resistance $81.82. The 52-week range is $40.14 to $90.75; price is 29.6% below the high and 59.1% above the low. The VWAP anchored at the 52-week high is $67.49, above price.
Performance
PCVX returned +3.0% (1 week), -1.8% (1 month), +9.6% (3 months), +20.5% (6 months), +58.4% (1 year), +38.5% (year to date).
About Vaxcyte, Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Biological Products, (No Diagnostic Substances) · Listed 2020 · 507 employees
Recent news
- Vaxcyte, Inc.: Ownership stake amendedSEC EDGAR · Fri, Nov 6, 2026
- Vaxcyte, Inc.: Earnings resultsSEC EDGAR · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in PCVX · 7 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Gilbert Cisneros house · D · CA · traded 2026-07-16 | Buy | $1K–$15K | 2026-07-16 | 2026-09-04 | |
Gilbert Cisneros house · CA · traded 2026-05-13 | Buy | $1K–$15K | 2026-05-13 | 2026-06-05 | |
Gilbert Cisneros house · CA · traded 2026-05-12 | Buy | $1K–$15K | 2026-05-12 | 2026-06-05 | |
Gilbert Cisneros house · D · CA · traded 2025-04-14 | Buy | $1K–$15K | 2025-04-14 | 2025-05-06 | |
Gilbert Cisneros house · D · CA · traded 2025-04-15 | Buy | $1K–$15K | 2025-04-15 | 2025-05-06 | |
Gilbert Cisneros house · D · CA · traded 2025-04-28 | Buy | $1K–$15K | 2025-04-28 | 2025-05-06 | |
 Jefferson Shreve house · R · IN · traded 2025-03-05 | Sell | $15K–$50K | 2025-03-05 | 2025-04-11 |
Insider activity
SEC Form 4 transactions in PCVX · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Cowan Elvia SVP, Finance & CAO · Common Stock · 2026-11-02 | Exercise | 3K | $78K | 2026-11-02 | 2026-11-04 |
Cowan Elvia SVP, Finance & CAO · Common Stock · 2026-11-02 | Sell | 586 | $36K | 2026-11-02 | 2026-11-04 |
Wassil Jim EVP, Chief Scientific Ofc, COO · Common Stock · 2026-11-02 | Exercise | 2.25K | $12K | 2026-11-02 | 2026-11-04 |
Cowan Elvia SVP, Finance & CAO · Stock Option (right to buy) · 2026-11-02 | Exercise | 3K | — | 2026-11-02 | 2026-11-04 |
Wassil Jim EVP, Chief Scientific Ofc, COO · Common Stock · 2026-11-02 | Sell | 1.91K | $116K | 2026-11-02 | 2026-11-04 |
Wassil Jim EVP, Chief Scientific Ofc, COO · Common Stock · 2026-11-02 | Sell | 343 | $21K | 2026-11-02 | 2026-11-04 |
Wassil Jim EVP, Chief Scientific Ofc, COO · Stock Option (right to buy) · 2026-11-02 | Exercise | 2.25K | — | 2026-11-02 | 2026-11-04 |
Cowan Elvia SVP, Finance & CAO · Common Stock · 2026-11-02 | Sell | 2.41K | $147K | 2026-11-02 | 2026-11-04 |
Cowan Elvia SVP, Finance & CAO · Stock Option (right to buy) · 2026-10-05 | Exercise | 19K | — | 2026-10-05 | 2026-10-07 |
Wassil Jim EVP, Chief Scientific Ofc, COO · Stock Option (right to buy) · 2026-10-05 | Exercise | 18K | — | 2026-10-05 | 2026-10-07 |
SEC filings
EDGAR filings in PCVX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.